Leap Therapeutics (FRA:5MC) FCF Margin % : 0.00% (As of Sep. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Leap Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Leap Therapeutics's Free Cash Flow for the three months ended in Sep. 2024 was €-14.06 Mil. Leap Therapeutics's Revenue for the three months ended in Sep. 2024 was €0.00 Mil. Therefore, Leap Therapeutics's FCF Margin % for the quarter that ended in Sep. 2024 was 0.00%.

As of today, Leap Therapeutics's current FCF Yield % is -310.15%.

The historical rank and industry rank for Leap Therapeutics's FCF Margin % or its related term are showing as below:

During the past 12 years, the highest FCF Margin % of Leap Therapeutics was -1730.47%. The lowest was -2343.80%. And the median was -2037.14%.

FRA:5MC's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -139.23
* Ranked among companies with meaningful FCF Margin % only.

Leap Therapeutics FCF Margin % Historical Data

The historical data trend for Leap Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Leap Therapeutics FCF Margin % Chart

Leap Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-1,730.49

-2,342.92

Leap Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Leap Therapeutics's FCF Margin %

For the Biotechnology subindustry, Leap Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Leap Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Leap Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Leap Therapeutics's FCF Margin % falls into.

Leap Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Leap Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-40.122	/	0
	=	%

Leap Therapeutics's FCF Margin for the quarter that ended in Sep. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Sep. 2024 )	/	Revenue (Q: Sep. 2024 )
	=	-14.056	/	0
	=	%

Leap Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Leap Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Leap Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Leap Therapeutics Inc (FRA:5MC) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

LPTX:USA 5MC:Germany

Address

47 Thorndike Street, Suite B1-1, Cambridge, MA, USA, 02141

Website

https://www.leaptx.com

Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .

Leap Therapeutics Headlines

No Headlines